Shareholders of Jubilant Pharmova have approved the re-appointment of its top leadership, including Managing Director Mr. Priyavrat Bhartia and Joint Managing Director Mr. Arjun Shanker Bhartia, along with their respective remuneration packages. The approvals were secured via a postal ballot process that concluded on August 17, 2026.

The company disclosed the outcome pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both special resolutions received overwhelming support from the promoter group and public shareholders, reflecting strong confidence in the existing management structure.

Voting Results

The postal ballot was conducted through remote e-voting on the National Securities Depository Limited (NSDL) platform. The voting window opened on July 19, 2026, and closed on August 17, 2026. As of the cut-off date of July 10, 2026, there were 83,910 registered shareholders.

Re-appointment of Managing Director

The resolution to re-appoint Mr. Priyavrat Bhartia as Managing Director was passed with significant majority support. Promoter and promoter group shareholders voted unanimously in favor, holding 75,938,622 shares. Public institutional shareholders also showed strong support, with 99.41% of polled votes in favor.

Re-appointment of Joint Managing Director

Similarly, the resolution to re-appoint Mr. Arjun Shanker Bhartia as Joint Managing Director received near-unanimous approval. The promoter group again voted 100% in favor. Among public institutions, 99.61% of votes were cast in support, while public non-institutions showed 99.98% support.

Scrutinizer’s Report

Rupinder Singh Bhatia, a practicing Company Secretary, served as the independent scrutinizer for the postal ballot process. The scrutinizer confirmed that the remote e-voting process was conducted fairly and transparently in compliance with the Companies Act, 2013, and SEBI LODR Regulations. The e-voting system was monitored through a secured link provided by NSDL, and the process was unblocked in the presence of two independent witnesses after the deadline.

The company noted that promoters and the promoter group had no interest in either agenda item. The detailed voting results and the scrutinizer’s report are available on the company’s website and the NSDL e-voting portal.

Jubilant Pharmova Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange and the National Stock Exchange of India. The submission marks the formal release of its first-quarter FY27 performance data, allowing investors to assess the company's operational and financial standing following the period close.

The Board of Directors approved the financial results during a meeting held on August 10, 2026. Prior to board approval, the Audit Committee reviewed the figures to ensure compliance with accounting standards. The company published the results in Financial Express (English) and Hindustan & Jansatta (Hindi) newspapers on August 11, 2026, as required by regulatory norms.

The disclosure was made pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results are also accessible via QR codes published in the newspapers and on the company’s official website. Investors can view the complete standalone and consolidated statements at www.jubilantpharmova.com .

Regulatory Compliance and Disclosure

The filing confirms that the statutory auditors have issued their review reports alongside the financial results. Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited, signed the intimation letter dated August 11, 2026, requesting the exchanges to take the records on file. The submission aligns with Regulation 33 read with Regulation 47(1) of the SEBI LODR Regulations, 2015.

What This Means for Investors

The timely filing of Q1FY27 results provides transparency into Jubilant Pharmova’s early-year performance. While the specific revenue and profit figures are contained within the full financial statements linked on the company website, the approval by the Board and review by the Audit Committee signal that the financial position is verified. Shareholders can now analyze the detailed metrics to gauge the impact of market conditions on the company’s pharma operations.